pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
471
stories
Sep 22, 26
Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations
biospace
Sep 22, 26
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
Sep 22, 26
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
Sep 22, 26
Novo’s workforce reduction climbs to 13,000 to fuel R&D work
biospace
Sep 22, 26
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
Sep 22, 26
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
Sep 21, 26
Novo talks up drug launches in effort to win back investors
biopharma dive
Sep 21, 26
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
Sep 21, 26
STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
stat
Sep 21, 26
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
biospace
Sep 21, 26
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Sep 21, 26
STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work
stat
Sep 21, 26
Are healthcare systems really ready for GLP-1s?
biopharma dive
Sep 21, 26
Why is trust in science important?
stat
Sep 18, 26
STAT+: In a fight over denied claims, HCA sues out-of-state Blue Cross Blue Shield plan
stat
Sep 18, 26
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
Sep 17, 26
Definium’s new psychedelics data, and a reprieve for international scientists
stat
Sep 17, 26
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
Sep 16, 26
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
Sep 16, 26
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
fiercebiotech
Sep 16, 26
STAT+: House Democrats may use oversight powers to plan for health care overhaul
stat
Sep 15, 26
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
Sep 15, 26
STAT+: RFK Jr. returns to his roots
stat
Sep 15, 26
STAT+: FDA takes applications for new program to shorten drug approval times
stat
Sep 15, 26
STAT+: Medicare’s AI prior authorization pilot was rushed and full of problems, new documents reveal
stat
Sep 15, 26
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
fiercebiotech
Sep 14, 26
Abbott agrees to settlement over closure of largest baby formula plant in the U.S.
stat
Sep 14, 26
STAT+: How $500 explains Republican health policy, and the GLP-1 Rx wave
stat
Sep 14, 26
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
biospace
Sep 14, 26
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
← prev
page 7 of 16
next →